CRBP Corbus Pharmaceuticals Holdings, Inc.
Price Chart
Executive Summary
Corbus Pharmaceuticals appointed Nishant Saxena as its first Chief Business Officer with a two-year employment agreement, granting him 192,300 stock options and 58,300 RSUs as inducement equity. Separately, the company announced a May 26 conference call to discuss updated CRB-701 Phase 1/2 data at ASCO, including response durability and HNSCC subgroup analysis. The filing is routine executive hiring and a scheduled data update — no material financial impact or change in fundamentals.
Actionable Insight
The CRB-701 ASCO data call on May 26 is the primary catalyst — watch for response durability and HNSCC subgroup data that could derisk the registrational study. The CBO hire adds M&A and partnership expertise but has no immediate trading implication. Monitor the May 26 webcast for data that could move the stock.
Key Facts
- Nishant Saxena appointed Chief Business Officer effective May 21, 2026, with a 2-year employment term and $470,000 base salary
- Inducement equity grants: 192,300 stock options (25% cliff at 1 year, then monthly over 36 months) and 58,300 RSUs (25% annual vesting over 4 years)
- Non-compete period of 6 months post-employment; severance of 12 months base salary (3 months if termination before 1-year anniversary) outside Change in Control, 18 months during Change in Control Period
- Brent Pfeiffenberger received initial board equity: 24,700 stock options and 7,500 RSUs, each vesting in 3 equal annual installments
- Conference call scheduled for May 26, 2026 at 8:00 a.m. EDT to discuss updated CRB-701 Phase 1/2 data at ASCO (April 1, 2026 data cut)
- Key pipeline milestones: initiation of registrational study of CRB-701 in second-line HNSCC and completion of CANYON-1 Phase 1b study for CRB-913 (n=240)
Financial Impact
No material financial impact; executive compensation of $470K salary plus equity grants is standard for a C-level hire at a $180M market cap clinical-stage biotech
Risk Factors
- CRB-701 ASCO data may disappoint, particularly if durability or HNSCC subgroup results are weak
- Dilution from 192,300 options and 58,300 RSUs is modest (~0.3% of shares outstanding at $180M market cap) but adds to overhang
- No financial guidance or revenue data in this filing — company remains pre-revenue clinical-stage
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-233507 |
| Document: crbp-20260519.htm | 0001193125-26-233507 |
| Document: crbp-ex99_1.htm | 0001193125-26-233507 |
| Document: 0001193125-26-233507-index-headers.html | 0001193125-26-233507 |
| Document: 0001193125-26-233507-index.html | 0001193125-26-233507 |
| Document: 0001193125-26-233507.txt | 0001193125-26-233507 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
23d ago
|
8-K
| $7.91 $7.75 | ▼ −2.02% | ▼ −3.11% | $8.05 (+1.77%) |
|
May 21, 2026
28d ago
|
8-K
| $11.51 $7.64 | ▼ −33.62% | ▼ −35.22% | $8.05 (−30.06%) |
|
May 14, 2026
5w ago
|
8-K
| $11.98 $11.51 | ▼ −3.92% | ▼ −3.21% | $8.05 (−32.80%) |
|
May 12, 2026
5w ago
|
8-K
| $11.43 $9.95 | ▼ −12.95% | ▼ −13.03% | $8.05 (−29.57%) |
|
May 12, 2026
5w ago
|
Press Release
| $11.43 $9.95 | ▼ −12.95% | ▼ −13.03% | $8.05 (−29.57%) |
|
Apr 16, 2026
9w ago
|
8-K
| $10.59 $10.06 | ▼ −5.00% | ▼ −5.56% | $8.05 (−23.98%) |
|
Apr 14, 2026
9w ago
|
8-K
| $10.02 $10.30 | ▲ +2.74% | ▲ +1.35% | $8.05 (−19.66%) |
|
Apr 7, 2026
10w ago
|
8-K
| $9.71 $10.02 | ▲ +3.19% | ▼ −2.14% | $8.05 (−17.10%) |
|
Mar 23, 2026
12w ago
|
EFFECT
| $8.43 $8.60 | ▲ +2.02% | ▲ +5.58% | $8.05 (−4.51%) |
|
Mar 11, 2026
14w ago
|
S-3
| $9.59 $8.94 | ▲ +6.78% | ▲ +5.80% | $8.05 (+16.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access